基于粪便免疫化学检测的结直肠癌筛查项目中的结肠镜相关死亡率
该研究基于荷兰国家结直肠癌筛查项目,评估粪便免疫化学检测(FIT)阳性后行结肠镜者在30天内的结肠镜相关死亡率。2013年10月至2017年12月共172797名FIT阳性参与者接受结肠镜,其中13848例诊断为结直肠癌。报告的致死性并发症率为每1万FIT阳性受检者0.23例,超额死亡率为0.91例,可能结肠镜相关死亡为0.86例,其中50%为心血管事件。
要点
- FIT阳性后结肠镜报告的致死性并发症率为每1万受检者0.23例(1/43199)。
- 基于超额死亡率的结肠镜相关死亡率为每1万受检者0.91例(1/10961)。
- 可能结肠镜相关死亡中50%为心血管事件,提示登记系统存在漏报。
核心结论
- 荷兰FIT筛查项目中结肠镜相关死亡率估计为每1万FIT阳性受检者0.23至0.91例。
- 登记系统存在致死性并发症漏报,致死性心血管不良事件发生率值得注意,需进一步研究。
- FIT筛查的危害远小于其获益。
研究设计与样本
- 基于荷兰国家内镜并发症数据库、国家筛查数据库及荷兰统计局死因登记数据的分析。
- 纳入2013年10月至2017年12月荷兰国家结直肠癌筛查项目中FIT阳性后接受结肠镜的172797名参与者。
- 其中13848名参与者诊断为结直肠癌。
主要发现
- 报告的致死性并发症率为每1万FIT阳性受检者0.23例(1/43199;95%CI 0.090-0.60)。
- 基于超额死亡率的结肠镜相关死亡率为每1万FIT阳性受检者0.91例(1/10961;95%CI 0.44-1.38)。
- 可能结肠镜相关死因为每1万FIT阳性受检者0.86例(1/11236;95%CI 0.48-1.63),其中50%为心血管事件。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND & AIMS: Many countries have introduced colorectal cancer (CRC) screening programs with fecal immunochemical tests (FITs), and follow-up colonoscopies for individuals with a positive FIT result. In order to make an informed decision to participate, individuals must be informed about the benefits and harms of FIT-based screening and subsequent colonoscopy. Colonoscopy-related fatal complications in FIT-based screening are understudied. We aimed to estimate the colonoscopy-related mortality in a national FIT-based CRC screening program. METHODS: Colonoscopy-related mortality within 30 days after colonoscopy was assessed by analysis of data from national endoscopy complication databases in the Netherlands, determining the excess 30-day rate of death in FIT-positive individuals undergoing colonoscopy vs FIT-negative individuals (based on data from the national screening database), and determining the rate of likely colonoscopy-related deaths based on registered causes of death by the Statistics Netherlands. RESULTS: Between October 2013 and December 2017, 172,797 participants underwent colonoscopy after a positive result from a FIT in the Dutch national CRC screening program; 13,848 participants received a diagnosis of CRC. The reported fatal complication rate was 0.23 per 10,000 FIT-positive participants (or 1 per 43,199; 95% CI, 0.090 - 0.60) undergoing colonoscopy, whereas this was 0.91 per 10,000 FIT-positive participants (or 1 per 10,961; 95% CI, 0.44 - 1.38) according to the excess death rate. Likely colonoscopy-related causes of death were reported in 0.86 per 10,000 FIT-positive participants (or 1 per 11,236; 95% CI, 0.48 - 1.63) who underwent colonoscopy, of which 50% considered cardiovascular events. CONCLUSIONS: Colonoscopy-related mortality within the Dutch FIT-based CRC screening program was estimated to range from 0.23 to 0.91 per 10,000 FIT-positive participants undergoing colonoscopy. These findings indicate underreporting of fatal complications in registries and a noteworthy incidence of fatal cardiovascular adverse events that requires further investigation. Nevertheless, the harm of FIT-based CRC screening is vastly outweighed by the benefits.
引用
- Kooyker AI, Toes-Zoutendijk E, Opstal-van Winden AWJ, et al. Colonoscopy-Related Mortality in a Fecal Immunochemical Test-Based Colorectal Cancer Screening Program. Clin Gastroenterol Hepatol. 2020. PMID: 32777553. doi:10.1016/j.cgh.2020.07.066
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。